138 related articles for article (PubMed ID: 12030785)
1. Mechanisms of resistance to rapamycins.
Huang S; Houghton PJ
Drug Resist Updat; 2001 Dec; 4(6):378-91. PubMed ID: 12030785
[TBL] [Abstract][Full Text] [Related]
2. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.
Xu G; Zhang W; Bertram P; Zheng XF; McLeod H
Int J Oncol; 2004 Apr; 24(4):893-900. PubMed ID: 15010827
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
[TBL] [Abstract][Full Text] [Related]
5. Rapamycins: mechanism of action and cellular resistance.
Huang S; Bjornsti MA; Houghton PJ
Cancer Biol Ther; 2003; 2(3):222-32. PubMed ID: 12878853
[TBL] [Abstract][Full Text] [Related]
6. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M; Rowinsky EK
Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
[TBL] [Abstract][Full Text] [Related]
7. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
Neshat MS; Mellinghoff IK; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons JJ; Wu H; Sawyers CL
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10314-9. PubMed ID: 11504908
[TBL] [Abstract][Full Text] [Related]
8. Halcyon days of TOR: Reflections on the multiple independent discovery of the yeast and mammalian TOR proteins.
Livi GP
Gene; 2019 Apr; 692():145-155. PubMed ID: 30639424
[TBL] [Abstract][Full Text] [Related]
9. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
Panwalkar A; Verstovsek S; Giles FJ
Cancer; 2004 Feb; 100(4):657-66. PubMed ID: 14770419
[TBL] [Abstract][Full Text] [Related]
10. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
[TBL] [Abstract][Full Text] [Related]
11. Predicted mechanisms of resistance to mTOR inhibitors.
Kurmasheva RT; Huang S; Houghton PJ
Br J Cancer; 2006 Oct; 95(8):955-60. PubMed ID: 16953237
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin resistance in ataxia-telangiectasia.
Beamish H; Williams R; Chen P; Khanna KK; Hobson K; Watters D; Shiloh Y; Lavin M
Oncogene; 1996 Sep; 13(5):963-70. PubMed ID: 8806686
[TBL] [Abstract][Full Text] [Related]
13. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
14. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
15. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Wu L; Birle DC; Tannock IF
Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
[TBL] [Abstract][Full Text] [Related]
16. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.
Dudkin L; Dilling MB; Cheshire PJ; Harwood FC; Hollingshead M; Arbuck SG; Travis R; Sausville EA; Houghton PJ
Clin Cancer Res; 2001 Jun; 7(6):1758-64. PubMed ID: 11410517
[TBL] [Abstract][Full Text] [Related]
17. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
18. Regulation of translation initiation by FRAP/mTOR.
Gingras AC; Raught B; Sonenberg N
Genes Dev; 2001 Apr; 15(7):807-26. PubMed ID: 11297505
[No Abstract] [Full Text] [Related]
19. Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins.
Wang X; Beugnet A; Murakami M; Yamanaka S; Proud CG
Mol Cell Biol; 2005 Apr; 25(7):2558-72. PubMed ID: 15767663
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells.
Metcalfe SM; Canman CE; Milner J; Morris RE; Goldman S; Kastan MB
Oncogene; 1997 Oct; 15(14):1635-42. PubMed ID: 9349496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
